Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer
- PMID: 19943768
- DOI: 10.3109/10611860903434050
Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer
Abstract
Application of daunorubicin in treatment of leukemia has been limited for its side effects like cardiotoxicity. Specific delivery of chemotherapy drugs is an important factor in decreasing their side effects. In this study, sgc8, an aptamer for protein tyrosine kinase-7 (PTK7), was used for specific delivery of daunorubicin to Molt-4 cells (PTK7(+)). Flow cytometric experiments showed that aptamer-daunorubicin complex was internalized effectively to Molt-4 cells (PTK7(+)), but not to U266 cells (PTK7(-)). This fact was confirmed by less cytotoxicity of aptamer-drug complex in U266 cells in compare to daunorubicin alone. No significant change in viability between daunorubicin and aptamer-daunorubicin complex treated Molt4 cells was observed. In conclusion, sgc8-daunorubicin complex is introduced as a simple and efficient system for targeted delivery of drug to acute lymphoblastic leukemia T cells.
Similar articles
-
Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.Int J Pharm. 2015 Jul 15;489(1-2):311-7. doi: 10.1016/j.ijpharm.2015.04.072. Epub 2015 Apr 29. Int J Pharm. 2015. PMID: 25936625
-
Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes.Eur J Pharm Biopharm. 2011 Feb;77(2):200-6. doi: 10.1016/j.ejpb.2010.12.005. Epub 2010 Dec 17. Eur J Pharm Biopharm. 2011. PMID: 21168488
-
Cell-specific internalization study of an aptamer from whole cell selection.Chemistry. 2008;14(6):1769-75. doi: 10.1002/chem.200701330. Chemistry. 2008. PMID: 18092308
-
An overview of Sgc8 aptamer as a potential theranostic agent for cancer with PTK7 oncogenic target.Sci Prog. 2025 Jan-Mar;108(1):368504251325385. doi: 10.1177/00368504251325385. Sci Prog. 2025. PMID: 40033943 Free PMC article. Review.
-
Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.J Control Release. 2013 Oct 28;171(2):152-62. doi: 10.1016/j.jconrel.2013.06.006. Epub 2013 Jun 15. J Control Release. 2013. PMID: 23777885 Review.
Cited by
-
Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.Pharm Res. 2016 Sep;33(9):2289-97. doi: 10.1007/s11095-016-1967-4. Epub 2016 Jun 9. Pharm Res. 2016. PMID: 27283831
-
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update.Pharmaceuticals (Basel). 2016 Nov 3;9(4):69. doi: 10.3390/ph9040069. Pharmaceuticals (Basel). 2016. PMID: 27827876 Free PMC article. Review.
-
Aptamers: Cutting edge of cancer therapies.Mol Ther. 2021 Aug 4;29(8):2396-2411. doi: 10.1016/j.ymthe.2021.06.010. Epub 2021 Jun 17. Mol Ther. 2021. PMID: 34146729 Free PMC article. Review.
-
Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.Target Oncol. 2015 Dec;10(4):467-85. doi: 10.1007/s11523-015-0371-z. Target Oncol. 2015. PMID: 25989948 Review.
-
Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.Protein J. 2016 Apr;35(2):81-99. doi: 10.1007/s10930-016-9653-2. Protein J. 2016. PMID: 26984473 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous